HWHG(SH:600079) 智通财经网·2025-11-03 07:49Core Viewpoint - The announcement highlights that Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of Pregabalin sustained-release tablets, indicating a significant step in expanding its treatment applications [1] Company Summary - Renfu Pharmaceutical holds an 80% stake in Yichang Renfu Pharmaceutical, which has recently been granted a clinical trial approval for Pregabalin sustained-release tablets [1] - The initial approval in 2023 was for the treatment of diabetic peripheral neuropathy (DPN) related neuropathic pain, and the new application aims to include postherpetic neuralgia (PHN) as an additional indication [1] Industry Summary - Pregabalin is identified as a novel calcium channel modulator that effectively blocks voltage-dependent calcium channels, thereby reducing the release of neurotransmitters [1] - The clinical applications of Pregabalin primarily target neuropathic pain associated with DPN and PHN, which are significant areas in pain management within the pharmaceutical industry [1]